NEW YORK – Last December, Spectrum Pharmaceuticals said that its drug candidate poziotinib failed to meet the pre-specified primary endpoint of overall response rate in the first cohort of participants in a Phase II clinical trial investigating the therapy in EGFR exon 20-mutated non-small cell lung cancer (NSCLC).